Novo Nordisk’s Ozempic, grappling with Eli Lilly’s Trulicity for supremacy of the GLP-1 diabetes market, hit a snag last year when the FDA refused to review a new dosing regimen over the need for more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback